|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||145445.32 g·mol−1|
|(what is this?)|
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.
At February 19, 2019 the co-development partners - Eli Lilly and Pfizer - announced that treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in chronic low back pain at 16 weeks compared to placebo (however, 5 mg arm demonstrated a numerical improvement in pain, but did not reach statistical significance compared to placebo at the week 16 analysis).
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|